Tissue Collection for Studies of Lymph Cancer

This observational study aims to collect samples from people with different types of lymph cancer or precancerous conditions. Researchers want to better understand these conditions, including Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. By studying blood, urine, bone marrow, and tissue samples, they hope to develop new ways to diagnose and treat these diseases. You may be able to join if you are at least 18 years old and have a known lymphoid malignancy (cancer of the lymph system) or a condition that could lead to it. The main goal is to acquire these samples for ongoing research.

Study design: This is an observational study planning to enroll 1295 participants. It is not a treatment study, but rather focuses on collecting biological samples.
What's involved: You will undergo a physical exam and medical history screening. Different types of samples, such as blood, urine, bone marrow, and tumor/skin tissue, will be collected for study.
Compensation: Not stated in the trial record.
Follow-up: Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Tissue Collection for Studies of Lymph Cancer

Recruiting

Not specifiedAges 18+Observational

National Cancer Institute (NCI)

~1,295 participants

Updated 2026-08-27 on ClinicalTrials.gov

At a glance

Recruiting sites

1 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

sample acquisition

Measured over ongoing

Conditions

Hodgkin Disease

Lymphoma, Non-Hodgkin

Multiple Myeloma

Lymphomatoid Granulomatosis

Leukemia-Lymphoma, Adult T-Cell

Where it's being run

2 sites across 2 states

Maryland1

Jamaica1

Study leadership

Christopher J Melani, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

NCIMO Referral Office

[email protected]

(888) 624-1937

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).

Confirmation of pathological diagnosis is required from the Laboratory of Pathology, NCI. Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care or required testing on an NIH research protocol will be used for diagnosis.

Age \>= 18 years of age

Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document NOTE: Patients enrolling with a LAR must be co-enrolled on another study.

Patients without a known lymphoid malignancy or lymphoid precursor diagnosis who have a planned surgical procedure during which blood or normal lymph node(s)/tissue (i.e., those not with pre-determined likelihood of abnormality/ malignancy) may be obtained for research studies as part of this protocol.

Age \>= 18 years of age

Must be able and willing to sign informed consent

Exclusion

Pregnant individuals will not be eligible.

Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, and/or pulmonary dysfunction.

Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.

Pregnant individuals will not be eligible.

Other active malignancy. NOTE: Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin as well as any in situ carcinoma are eligible. Patients with a malignancy that has been treated with curative intent and who are without evidence of disease for \>=2 years will also be eligible at the discretion of the investigator.

Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.

What this trial measures

sample acquisitionongoing
Standard exploratory and descriptive statistical methods will be used, as appropriate to the specific biologic assay. Any findings will be reported in the context of this exploratory study, with appropriate caveats.

Trialytics